Advanced search
Publication Cover
HIV Research & Clinical Practice Volume 20, 2019 - Issue 4-5
Submit an article Journal homepage
3,182
Views
17
CrossRef citations to date
0
Altmetric
Original Article

Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

Miranda MurrayViiV Healthcare, London, UK; View further author information
,
Federico PulidoHospital Universitario 12 de Octubre, UCM, (imas12), Madrid, Spain; View further author information
,
Anthony MillsSouthern California Men’s Medical Group, West Hollywood, CA, USA; View further author information
,
Moti RamgopalMidway Immunology and Research Center, Fort Pierce, FL, USA; View further author information
,
Roger LeBlancImmunodeficiency Service Division of Hematology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada; View further author information
,
Hans JaegerHIV Research and Clinical Care Centre, MUC Research GmbH and MVZ Karlsplatz, Munich, Germany; View further author information
,
Viviam CanonDivision of Janssen Pharmaceutica NV, Janssen Research & Development, Beerse, Belgium; View further author information
,
David DoreyGlaxoSmithKline, Mississauga, Ontario, Canada; View further author information
,
Sandy GriffithViiV Healthcare, Research Triangle Park, NC, USAORCID Iconhttp://orcid.org/0000-0002-3430-5131View further author information
ORCID Icon,
Joseph MrusViiV Healthcare, Research Triangle Park, NC, USAView further author information
,
William SpreenViiV Healthcare, Research Triangle Park, NC, USAView further author information
&
David MargolisViiV Healthcare, Research Triangle Park, NC, USACorrespondence[email protected]
View further author information
 show all
Pages 111-122 | Received 22 Mar 2019, Accepted 02 Aug 2019, Published online: 18 Sep 2019

References

  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Rockville, MD: US Department of Health and Human Services; 2018. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed January 22, 2019.
  • Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11–19.
  • Vitoria M, Ford N, Doherty M, Flexner C. Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings. Antivir Ther. 2014;19(suppl 3):31–37.
  • Margolis DA, Boffito M. Long-acting antiviral agents for HIV treatment. Curr Opin HIV Aids. 2015;10(4):246–252.
  • Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–1510.
  • Spreen WR, Margolis DA, Pottage J. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013;8(6):565–571.
  • Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14(5):192–203.
  • Ford SL, Gould E, Chen S, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother. 2013;57(11):5472–5477.
  • Edurant [package insert]. Titusville, NJ: Janssen Therapeutics;2011; revised 2017. https://www.janssencarepath.com/sites/www.janssencarepath.com/files/prescribing-information-edurant.pdf. Accessed January 22, 2019.
  • Williams PE, Crauwels HM, Basstanie ED. Formulation and pharmacology of long-acting rilpivirine. Curr Opin HIV Aids. 2015;10(4):233–238.
  • Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health. 2006;9(5):320–333.
  • Romaine J, Murray M, Bradley C. Psychometric evaluation of the revised HIV Treatment Satisfaction Questionnaire (HIVTSQ). Abstract presented at: Annual European Congress of the International Society For Pharmacoeconomics and Outcomes Research; October 29–November 2, 2016; Vienna, Austria.
  • The Health Psychology Research Group. HIVTSQ Guidelines. London: Royal Holloway of the University of London; 2015.
  • Simoni JM, Beima-Sofie K, Mohmed ZH, Collier AC, Ho R. Acceptability of long-acting injectable ART: provider and patient preferences. Poster presented at Adherence 2017; June 4–6, 2017; Miami, FL.
  • Kerrigan D, Mantsios A, Gorgolas M, et al. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS One. 2018;13(1):e0190487.
  • World Health Organization (WHO) Support for Country Impact. Progress Report 2016: Prevent HIV, Test and Treat All. Geneva: WHO; 2016. http://www.who.int/hiv/pub/progressreports/2016-progress-report/en. Accessed January 22, 2019.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.